This site is intended for healthcare professionals only

DiabetesontheNet Logo
×


Diabetes Digest

Issue:

Share this article
Share on facebook
Share on twitter
Share on email
Share on print

Insulin degludec in people prone to nocturnal severe hypoglycaemia

In results consistent with clinical trials, degludec reduces hypoglycaemia compared with glargine in this at-risk group.

Insulin degludec (Tresiba) has previously been demonstrated to reduce nocturnal hypoglycaemia in people with type 1 diabetes; however, insulin trials typically exclude individuals who are at high risk of hypoglycaemia. Therefore, the present trial sought to compare insulin degludec U100 with insulin glargine U100 in individuals at high risk of severe nocturnal hypoglycaemia.

A total of 149 people with type 1 diabetes who had experienced one or more episodes of severe nocturnal hypoglycaemia were enrolled in a 2-year, crossover study with a prospective, randomised, open-label, blinded-endpoint design. They were assigned in a randomised order to receive degludec or glargine, both in a basal–bolus regimen with insulin aspart as the short-acting insulin. Both treatment arms involved a 3-month titration period followed by a 9-month maintenance period. As the participants were prone to hypoglycaemia, glycaemic targets were set to maintain the baseline level of control in both treatment arms.

The primary outcome was the number of episodes of blindly adjudicated nocturnal hypoglycaemia. Treatment with degludec reduced the relative rate of level 1 hypoglycaemia (≤3.9 mmol/L) by 28%, and level 2 hypoglycaemia (≤3.0 mmol/L) by 37%. The relative rate of severe hypoglycaemia at any time was reduced by 35%. The absolute risk of nocturnal hypoglycaemia was estimated to be reduced by 0.8 events per person-year.

These results are consistent with those observed in the clinical trials of insulin degludec. Although the open-label design is a weakness of the study, this was partially compensated for by the blinded adjudication of the results. The authors thus conclude that treatment with insulin degludec reduces the risk of nocturnal and severe hypoglycaemia in people with type 1 diabetes who are at risk of these complications.

Click here to read the study in full.

Share this article
Share on facebook
Share on twitter
Share on linkedin
Share on email
Share on whatsapp
Related content
For the latest news and articles

Sign up to all DiabetesontheNet journals

© Copyright Omniamed Communications. All Rights Reserved​
108 Cannon Street, London, EC4N 6EU. Registered in the United Kingdom​
Omniamed logo white
DiabetesontheNet Logo
For the latest news and articles

Sign up to all DiabetesontheNet journals

 

By clicking ‘Subscribe’, you are agreeing that DiabetesontheNet.com are able to email you periodic newsletters. You may unsubscribe from these at any time. Your info is safe with us and we will never sell or trade your details. For information please review our Privacy Policy.

DiabetesontheNet Logo

This website is for healthcare professionals only. To continue, please confirm that you are a healthcare professional below.